H.R. 2640 · 108th Congress
Prescription Affordability and Medicine Safety Act of 2003
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 108th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
KennedySponsor6 cosponsors · 5 D, 1 I
2 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Prescription Affordability and Medicine Safety Act of 2003 - Authorizes appropriations for the Food and Drug Administration (FDA) for generic drug application review and the continuation of the education program on the use and therapeutic equivalency of drugs.
What it does: CRS summary · Introduced in House · Jun 26, 2003
Prescription Affordability and Medicine Safety Act of 2003 - Authorizes appropriations for the Food and Drug Administration (FDA) for generic drug application review and the continuation of the education program on the use and therapeutic equivalency of drugs.
Amends the Public Health Service Act to authorize the Secretary of Health and Human Services to make grants to States in support of State pharmacy benefit assistance programs. Requires a percentage of profits from the sale of certain drugs and biological products to be placed in a revolving fund and used to support the grants program.
Limits the tax deductions for advertising for prescription drug manufacturers.
Limits the extension of the 30-month stay of FDA approval for any new (generic) drug, as specified, thereby limiting the brand name drug's patent owner's period of exclusive sales.
Makes a patent owner's failure to timely file a civil action for infringement a bar to later action.
Sets forth requirements for filing drug patent information with the FDA. Makes a patent owner's failure to timely file with the FDA a bar to civil actions for patent infringement.
Requires the first generic drug applicant with a specified certification to forfeit the 180-day marketing exclusivity period to a subsequent generic drug applicant if the first generic drug applicant engages in certain behaviors which delay or prevent the marketing of the generic drug.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Prescription Affordability and Medicine Safety Act of 2003
Latest action (Jul 11, 2003): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Jun 26, 2003
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.